Pharming (ADR) (PHAR)
Commercializes rare-disease medicines while advancing a mitochondrial-disease program.
$11.21
At close+0.08 (+0.72%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67 | 81 | 56 | 74 | 75 | 92,700 | 79 | 93 | 97 | 107 | 72 | 90 |
| Cost of revenue | 8 | 7 | 8 | 8 | 7 | 12,200 | 8 | 9 | 7 | 21 | 7 | 15 |
| Gross profit | 58 | 74 | 47 | 66 | 68 | 80,500 | 71 | 84 | 90 | 85 | 66 | 76 |
| 56 | 73 | 64 | 69 | 65 | 73,900 | 78 | 75 | 74 | 83 | 71 | 76 | |
| Research & development | 21 | 12 | 19 | 22 | 21 | 22,300 | 21 | 24 | 23 | 32 | 26 | 32 |
| 36 | −30 | 45 | 49 | 44 | 51,600 | 57 | 52 | 51 | 51 | 46 | 44 | |
| Selling & marketing | 25 | −79 | 30 | 33 | 29 | 26,900 | 35 | 31 | 34 | 31 | 30 | 29 |
| General & administrative | 11 | 49 | 15 | 16 | 15 | 24,700 | 22 | 21 | 17 | 20 | 15 | 15 |
| Other expenses | 0 | 92 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 2 | 1 | −16 | −3 | 3 | 6,600 | −7 | 9 | 16 | 2 | −5 | 0 |
| 1 | −3 | 0 | 3 | −2 | 100 | −4 | −2 | −3 | 3 | 1 | 3 | |
| Interest income | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 0 |
| Interest expense | 0 | 5 | 2 | 2 | 3 | 1 | 5 | 0 | 8 | 1 | 3 | 3 |
| Other non-operating income | 0 | 2 | −1 | −5 | −1 | −100 | −1 | 2 | −5 | −4 | −3 | −6 |
| Income before tax | 3 | −2 | −17 | 0 | 2 | 6,700 | −12 | 7 | 13 | 5 | −5 | 3 |
| Income tax expense | 0 | 1 | −4 | 1 | 3 | 3,800 | 3 | 3 | 5 | −1 | 0 | 1 |
| Net income from continuing operations | 3 | −3 | −12 | −1 | −1 | 2,900 | −15 | 5 | 8 | 5 | −5 | 2 |
| Net income | 3 | −3 | −12 | −1 | −1 | 2,900 | −15 | 5 | 8 | 5 | −5 | 2 |
| EPS, basic | $0.05 | −$0.04 | −$0.15 | −$0.01 | −$0.02 | $0.05 | −$0.22 | $0.07 | $0.11 | $0.08 | −$0.08 | $0.02 |
| EPS, diluted | $0.05 | −$0.04 | −$0.15 | −$0.01 | −$0.02 | $0.05 | −$0.22 | $0.07 | $0.11 | $0.07 | −$0.08 | $0.02 |
| Weighted average shares, basic | 82 | 84 | 84 | 85 | 65 | 68 | 67 | 67 | 67 | 66 | 70 | 70 |
| Weighted average shares, diluted | 82 | 84 | 84 | 85 | 65 | 68 | 67 | 67 | 67 | 76 | 70 | 70 |
| EBITDA | 5 | 7 | −9 | 2 | 7 | 6,708 | −4 | 10 | 23 | 9 | 1 | 9 |
| Depreciation & amortization | 3 | 8 | 6 | 0 | 3 | 8 | 3 | 3 | 3 | 3 | 3 | 3 |
| EBIT | 2 | −1 | −15 | 2 | 5 | 6,700 | −7 | 7 | 21 | 6 | −2 | 6 |